In the past 15 years, the field of metabolomics has expanded the current understanding of the pathophysiology of diabetic complications far beyond oxidative stress and inflammation. Branched-chain amino acids, phospholipid metabolism, and the glutamine/glutamate cycle are just a few of the previously unknown pathways and biomarkers of diabetes which have come to light due to advancements in sensitivity, sample preparation, and data processing.